AbbVie's (ABBV) Cariprazine Met Primary Endpoint in Phase 3 Study as an Adjunctive Treatment for Major Depressive Disorder

AbbVie (ABBV) Announces FDA Approval of VUITY 1.25%, the First and Only Eye Drop to Treat Presbyopia

Allergan, an AbbVie (NYSE: ABBV) company, today announced the U.S. Food and Drug Administration (FDA) approval of VUITY (pilocarpine HCl ophthalmic solution) 1.25% for the treatment of presbyopia, commonly known as age-related blurry near vision, in adults. VUITY is the first and only FDA-approved eye drop to treat this common and progressive eye condition that affects 128 million Americans, nearly half of the U.S. adult population.

"Most adults cope with presbyopia, or difficulty with near vision, as we age. Beginning around the age of 40, many find themselves using reading glasses, holding text... More

AddVie (ABBV) Continues to Deliver, Despite Concerns - Analyst

Earlier today, AbbVie (NYSE: ABBV) reported its Q3 results: EPS of $3.33, $0.10 better than the analyst estimate of $3.23; Revenue of $14.34 billion versus the consensus estimate of $14.35 billion.

The company also raised its adjusted diluted EPS for the full-year 2021 from $12.52 to $12.62 to $12.63 to $12.67.

Commenting on the earnings readout, Mizuho analyst Vamil Divan is encouraged by the company's continued strong performance and outlook, even as he awaits greater clarity... More

AbbVie (ABBV) Raises Quarterly Dividend 8.5% to $1.41; 5.1% Yield

AbbVie (NYSE: ABBV) declared a quarterly dividend of $1.41 per share, or $5.64 annualized. This is an 8.5% increase from the prior dividend of $1.30.

The dividend will be payable on February 15, 2022, to stockholders of record on January 14, 2022, with an ex-dividend date of January 13,... More

AbbVie (ABBV) Tops Q3 EPS by 10c, Offers Guidance

AbbVie (NYSE: ABBV) reported Q3 EPS of $3.33, $0.10 better than the analyst estimate of $3.23. Revenue for the quarter came in at $14.34 billion versus the consensus estimate of $14.35 billion.

GUIDANCE:

AbbVie sees FY2021 EPS of $12.63-$12.67, versus the consensus of... More

AbbVie (ABBV) call put ratio 8.8 calls to 1 put into quarter results

AbbVie (NYSE: ABBV) October weekly call option implied volatility is at 51, November is at 26; compared to its 52-week range of 18 to 40 into the expected release of quarter results before the bell on October 29. Call put ratio 8.8 calls to 1 put.

AbbVie (ABBV) Reports ABBV-951Showed Improvement in Controlling Motor Fluctuations Compared to Oral Levodopa/Carbidopa Medication in Pivotal Phase 3 Trial

AbbVie (NYSE: ABBV) today announced that continuous 24 hours/day subcutaneous infusion of ABBV-951 (foslevodopa/foscarbidopa) was statistically superior to oral levodopa/carbidopa in reducing motor fluctuations in patients with advanced Parkinson's disease (PD) in a Phase 3, randomized, double-blind, double-dummy, active-controlled study. The study met its primary endpoint of increase from baseline in "On" time (hours) without troublesome dyskinesia (involuntary movements) after 12 weeks based on the Parkinson's Disease Diary (PD Diary).1 These results will be a key component of global regulatory submissions.

The increase in "On" time at week 12 was 2.72 hours for ABBV-951 versus... More